Related Experiment Video
Updated: Mar 10, 2026
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Lipoprotein-associated phospholipase A2 in coronary heart disease: Review and meta-analysis
Dongze Li1, Lizhi Zhao2, Jing Yu3
1Department of Emergency Medicine, West China Hospital, Sichuan University, Chengdu, China.
Insights
Higher lipoprotein-associated phospholipase A2 (Lp-PLA2) levels are linked to increased cardiovascular events in coronary heart disease (CHD) patients. This association is particularly noted in stable CHD patients not on Lp-PLA2 inhibiting therapies.
Area of Science:
- Cardiovascular Medicine
- Biomarkers
- Clinical Research
Background:
- The prognostic significance of lipoprotein-associated phospholipase A2 (Lp-PLA2) in coronary heart disease (CHD) requires further clarification.
- Existing research presents conflicting associations between Lp-PLA2 levels and adverse outcomes in CHD patients.
Purpose of the Study:
- To conduct a meta-analysis investigating the association between Lp-PLA2 activity or mass and the prognosis of CHD.
- To clarify the risk associations between Lp-PLA2 and adverse outcomes in patients with established coronary heart disease.
Main Methods:
- A systematic literature search of PubMed and Embase was performed for prospective studies published before June 2016.
- Multivariate-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for adverse outcomes related to Lp-PLA2 were extracted and pooled using random-effect modeling.
Main Results:
- Fifteen studies comprising 30,857 participants were included in the meta-analysis.
- Elevated Lp-PLA2 activity or mass was not significantly associated with increased long-term all-cause mortality.
- Higher Lp-PLA2 activity or mass showed an independent association with an increased risk of long-term cardiovascular events (pooled HRs 1.55 and 1.62).
Conclusions:
- Increased Lp-PLA2 activity or mass is independently associated with cardiovascular events in patients with CHD.
- The predictive value of Lp-PLA2 for cardiovascular events is most evident in stable CHD patients not undergoing Lp-PLA2 inhibiting therapies.
Background:
Risk associations between lipoprotein-associated phospholipase A2 (Lp-PLA2) and adverse outcomes in patients with coronary heart disease (CHD) remain unclear. The aim of the meta-analysis was to investigate the association between Lp-PLA2 and prognosis of CHD.
Methods:
PubMed and Embase were examined for prospective studies published before June 2016. Multivariate-adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for the risk of adverse outcomes according to Lp-PLA2 activity or mass were extracted, pooled, and weighted using generic inverse-variance and random-effect modeling.
Results:
Fifteen studies with 30,857 participants were included. Overall, higher Lp-PLA2 activity or mass was not significantly related to increased risk of long-term all-cause mortality. However, higher Lp-PLA2 activity or mass was independently associated with an increased risk of long-term cardiovascular events, with pooled HR for cardiovascular events of 1.55 (95% CI, 1.08-2.23; P=0.018) and 1.62 (95% CI, 1.09-2.41; P=0.017), respectively. The prognostic value of Lp-PLA2 in predicting cardiovascular events was observed in patients with stable CHD who were not receiving therapies for inhibiting Lp-PLA2.
Conclusions:
Greater Lp-PLA2 activity or mass was independently associated with cardiovascular events in patients with CHD, particularly in patients with stable CHD who were not receiving therapies for inhibiting Lp-PLA2.
